⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5703418 | 0.94 | — | — | |
| SCHEMBL5703325 | 0.92 | — | — | |
| SCHEMBL5703284 | 0.92 | — | — | |
| SCHEMBL5703328 | 0.92 | — | — | |
| SCHEMBL10079088 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL31326323 | 0.85 | — | — | |
| SCHEMBL12328056 | 0.76 | — | — | |
| SCHEMBL21985004 | 0.74 | — | — | |
| SCHEMBL26597869 | 0.74 | — | — | |
| SCHEMBL420704 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116874466-A | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-112672791-B | N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors | 辉瑞公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023116934-A1 | KRASG12D PROTEIN HYDROLYSIS REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-112672791-A | N-substituted dioxocyclobutenylamino-3-hydroxy-pyridinecarboxamides useful as CCR6 inhibitors | 辉瑞公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-111225900-A | 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use | 阿勒根公司 | 2020-06-02 | — | — | CN | disclosed |